Ocuphire Pharma
safety summary from phase and phase studies way | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
21 of 114
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
October 2022
safety summary from phase and phase trials | Ocuphire Pharma
Related slides by other companies
ATAI
Investor Presentation
October 2023
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
Nuvalent
Investor Presentation
January 2024
the path to patient impact ams program status first approved and pivotal data study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product study for alk demonstrated clinical proof of concept in phase with mission bringing new best in class medicines to patients with cancer planned development in both and alk planned phase initiation in for her i | Nuvalent
BioNTech
Results
March 2022
phase first in human study of | BioNTech
BioNTech
Results
November 2020
phase a safety profile | BioNTech
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights